[Extracorporeal membrane oxygenation by acute respiratory distress syndrome].
After various observational studies demonstrated a benefit of extracorporeal membrane oxygenation (ECMO) in the therapy of severe acute respiratory distress syndrome (ARDS), ECMO now represents an important contribution for ARDS therapy using clinical algorithms despite a lack of positive controlled studies. In specialized centers patients with severe ARDS and imminent hypoxia despite intensive conventional therapy, are treated with ECMO using blood pumps and artificial membrane lungs (oxygenators) for extracorporeal lung assist. The development of new surface modifications, optimized oxygenators and miniaturized blood pumps should increase hemocompatibility and lead to simplified treatment as well as less complications. New oxygenators with significantly decreased blood resistance allow the clinical application of pumpless arteriovenous extracorporeal lung assist (ECLA). After these new developments indications for ECMO could be extended from use not only as ultimate ratio but to less severe ARDS to enable lung protective, less invasive mechanical ventilation.
Kopp
R
R
Klinik für Anästhesiologie, Universitätsklinikum der RWTH Aachen. ruedger.kopp@post.rwth-aachen.de
Henzler
D
D
Dembinski
R
R
Kuhlen
R
R
D000925:Anticoagulants / Q000627:therapeutic use; D015199:Extracorporeal Membrane Oxygenation / Q000295:instrumentation; D006801:Humans; D012128:Respiratory Distress Syndrome / Q000628:therapy*
D000925:Anticoagulants